cd19/baff-r in vivo car-t cell intravenous infusion
Acute Leukemia
Qi dengCell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
59 Active assets in the Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 2/3 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Cytosin-Arabinosid Janssen Research & Development, LLC | Phase 2/3 | BB |
ETOPOSIDE Nanfang Hospital, Southern Medical University | Phase 2/3 | BB |
METHOTREXATE SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
cd19/baff-r in vivo car-t cell intravenous infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →